Huntington’s disease research news. In plain language. Written by scientists. For the global HD community.

Are you looking for our logo? You can download our logo and get information about how to use it on our sharing page
Is Huntington’s disease twice as common as we thought?

Is Huntington’s disease twice as common as we thought?

Dr Ed Wild on November 27, 2010

In an article in the medical journal The Lancet, Sir Michael Rawlins claims that traditional estimates of how common Huntington’s disease is, might be dramatic underestimates. Why might this be, and what does it mean for the HD community and the search for effective treatments?

Two large HD observational studies – COHORT and Registry – merge to create ENROLL-HD

Two large HD observational studies – COHORT and Registry – merge to create ENROLL-HD

Dr Jeff Carroll on November 24, 2010

When it comes to studying a disease that progresses slowly, like HD, there is strength in numbers. Studying many patients repeatedly over several years can give us powerful insights that can’t be gained through other research techniques. That’s why two of the largest observational studies, COHORT and REGISTRY are joining forces to form ENROLL-HD, the world’s largest ever study of HD patients.

Huntexil for symptoms of Huntington's disease: where are we now?

Huntexil for symptoms of Huntington's disease: where are we now?

Dr Ed Wild on November 16, 2010

2010 was a big year for the small Danish pharmacology company NeuroSearch and its experimental drug, Huntexil, which aims to improve the movements and coordination of people with HD symptoms. What have NeuroSearch's two clinical trials - MermaiHD in Europe and HART in the USA - told us about the possible benefits of Huntexil - and what is likely to happen next?

Minocycline: the end of the road?

Minocycline: the end of the road?

Dr Ed Wild on November 10, 2010

The DOMINO study group has published the report of its ‘futility study’ of minocycline treatment in HD. Minocycline and a placebo pill were tested over 18 months. A futility study is designed to make it relatively easy for a drug to be recommended for larger studies, but minocycline treatment wasn’t promising enough and the study authors found that further trials with minocycline were “not warranted”.

TRACK-HD reveals significant changes in pre-symptomatic HD mutation carriers and patients

TRACK-HD reveals significant changes in pre-symptomatic HD mutation carriers and patients

Dr Jeff Carroll on November 01, 2010

TRACK-HD, an observational trial of people carrying the HD mutation has released data describing changes over the first year of the study. These data show that a number of changes can be robustly observed in a single year of observing HD patients, which could be used to help plan drug trials. Brain imaging, in particular, was able to clearly see changes caused by the HD mutation.